UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): May 714, 2009

Noven Pharmaceuticals, Inc.
__________________________________________
(Exact name of registrant as specified in its charter)


Delaware	0-17254	59-2767632
_____________________ (State or other jurisdiction	_____________ (Commission	______________ (I.R.S. Employer
of incorporation)	File Number)	Identification No.)

11960 S.W. 144th Street, Miami, Florida		33186
_________________________________ (Address of principal executive offices)		___________ (Zip Code)


Registrant’s telephone number, including area code:		305-253-5099

Not Applicable
______________________________________________
Former name or former address, if changed since last report

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

[  ]  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[  ]  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[  ]  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[  ]  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Top of the Form

Item 25.02 ~~Results~~Departure of ~~Operations~~Directors ~~and~~or ~~Financial~~Certain ~~Condition~~Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(d) On May 714, 2009, Dr. Francois E. Nader accepted an offer to join the Board of Directors of Noven Pharmaceuticals, Inc. ~~issued~~(the a"Company"), ~~press~~effective ~~release~~May ~~announcing~~22, ~~its~~2009, ~~financial~~immediately ~~results~~following ~~for~~ the ~~three~~Company’s ~~months~~2009 ~~ended~~Annual ~~March~~Meeting ~~31,~~of ~~2009~~Stockholders (the "Annual Meeting"). ~~This~~Because ~~press~~Dr. ~~release,~~Nader was not identified as a ~~copy~~director nominee prior to the mailing of ~~which~~the isCompany’s ~~attached~~proxy ~~hereto~~materials asfor ~~Exhibit~~the ~~99.1~~Annual Meeting, he is ~~"furnished"~~not ~~and~~among ~~shall~~the ~~not~~individuals benominated ~~deemed~~for ~~"filed"~~election ~~for~~at ~~purposes~~the ofAnnual ~~Section~~Meeting. Accordingly, 18his ofappointment to the ~~Securities~~Company’s ~~Exchange~~Board ~~Act~~ of ~~1934~~Directors ~~(the~~will ~~"Exchange~~become ~~Act")~~effective orimmediately ~~incorporated~~after bythe ~~reference~~Annual ~~into~~Meeting. Dr. aNader ~~filing~~is ~~under~~also expected to join the ~~Securities~~Audit ~~Act~~Committee of ~~1933~~the orCompany’s ~~the~~Board ~~Exchange~~of ~~Act~~Directors at that time.

Top of the Form

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Noven Pharmaceuticals, Inc.
May 7, 2009	By:	/s/ Jeff Mihm
May 15, 2009	By:	/s/ Jeff Mihm
		Name: Jeff Mihm
		Title: Vice President, General Counsel and Corporate Secretary

Top of the Form

Exhibit Index

Exhibit No.		Description
99.1		Press Release, dated May 7, 2009, announcing Noven Pharmaceuticals, Inc.'s financial results for the quarter ended March 31, 2009.

Filing Compare · NOVEN PHARMACEUTICALS INC